On August 29, 2017 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that it will feature two oral data presentations during the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2017 Congress, being held Sept. 8 – 12, 2017, in Madrid, Spain (Press release, Five Prime Therapeutics, AUG 29, 2017, View Source [SID1234520330]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Number and Title: 1616O – Multicenter, Nonrandomized, Open-Label Phase 1b Study of FP-1039/GSK3052230 with Chemotherapy: Results in Malignant Pleural
Mesothelioma (MPM)
Proffered Paper Session: Mesothelioma and SCLC
Session Date and Time: Sunday, Sept. 10, 2017, 9:15 – 10:45 a.m. CEST
Location: Barcelona Auditorium

Abstract Number and Title: 6PD – FPA150, a Novel B7-H4 Therapeutic Antibody with Checkpoint Blockade and ADCC Activities
Poster Discussion Session: Basic Science
Session Date and Time: Sunday, Sept. 10, 2017, 4:30 – 5:45 p.m. CEST
Location: Bilbao Auditorium